Credit Report (Nector Lifesciences Ltd)

1

CHAPTER 1 Company and its detail summarization

CHAPTER 2 Company worldwide location & subsidiaries detail

CHAPTER 3 Company cash flow and financial Status

CHAPTER 4 Aspects of international business

CHAPTER 5 Company strategies and future plans

CHAPTER 6Overall analysis and recommendations from our

side

Table of Content

2

Chapter 1

• Company and its Detail Summarization

• 1.1 Organization Business Overview

• 1.2 Company Type

• 1.3 Product Details

• 1.4 No. of Employees in Company

• 1.5 Total Revenue

• 1.6 Company Address, Contact number and Email I.d

• 1.7 Company Hierarchy of Designation

• 1.8 Company's Regulatory Certificates

• 1.9 Company’s Achievements

3

1.1 Organization Business Overview

4

Nectar Lifesciences Limited (NLL) is a pharmaceutical company in India

that founded in 1995

NLL has evolved from the manufacturer of oral and sterile range of APIs and FDFs to a composite pharmaceutical organization

Nectar Lifesciences manufactures oral & sterile active pharmaceutical ingredients, finished dosages and phytochemicals.

Nectar is the world's largest manufacturer and exporter of natural menthol and allied products.

It also manufactures empty hard gelatin capsules

The company is the largest GMP manufacturer of oral and sterile Cephalosporins in the world.

5

Nectar Lifescience is a ltd and litsted Company

Nectar Lifesciences Limited medium size pharmaceutical company

The company went public in July 2005 with simultaneous listings on Bombay Stock Exchange and the National Stock Exchange of India

The company is also in business of providing leading pharmaceutical organizations with contract research and manufacturing services.

1.2 Company Type

6

Name and Description of Product % to Total Turn Over of the Company

Drugs and Pharmaceuticals 86.80

Menthol (Phytochemical) 11.35

Diagnostics Kits 1.85

*In March 2011, the company received approval from

the Japanese MOH for their product, Cefuroxime

Axetil.

1.3 Product Details

7

Nectar family consists of over 2000 members

Revenue

1663.4

INR Cr.

Net Profit

66.26

INR Cr.

1.4 No. of Employees in Company

1.5 Total Revenue (FY-14-15)

8

Nectar Lifesciences Ltd

SCO 38-39, Sector 9d,

Chandigarh 160009,

India

Ph:+91172-3047777

Fax:+91172-3047755

Nectar Lifesciences Ltd

D-708, Crystal plaza,

Off New link Road,

Opp Infinitti Mall, Andheri (W),

Mumbai-400053

Ph:+9122-32060171

Fax:+9122-26736793

1.6 Company Address, Contact Number

Mrs. Rima Marphatia

(Non Executive Director)

Mr. Sanjive Goyal

(Chairman &Managing Director)

Mr. Dinesh Dua

(Chief Executive Officer and Director)

Mr. Raman Kapoor

(Director)

Dr. (Maj. Gen) S. S. Chauhan

(Director)

Mr. HarPrakash Gill

(Non Promoter Executive Director)

Mr. Ajay Swaroop

(Director)

Mr. Neera Singh

(Additional Director)

Mr. Vijay Shah

(Director)

Mr. Vivek Shett

(Director)

9

1.7 Company Management

ANVISA GMP approval received for formulation facility

In March 2011, the company received approval from the Japanese MOH for their product,

Cefuroxime Axetil.

CEP received for Cefotaxime sodium Sterile

NecLife has filed 44 Drug Master Files (DMFs) in highly regulated markets and 15

Abbreviated New Drug Applications (ANDAs). The company expects to file another 20

DMFs and 10 ANDAs/EU Dossiers from Dera Bassi and Baddi facilities in this fiscal year.

February 2012: Japanese PMDA approval received for

active pharmaceutical ingredients manufacturing

facility.

December 2011: European GMP approval received for

finished formulations manufacturing facility.

October 2011: European GMP approval received for active pharmaceutical ingredients

manufacturing facility.

September 2011: US Food and Drug Administration's approval received for active pharmaceutical ingredients

manufacturing facility.

Certification

10http://www.fortshare.net/CompanyProfile/ManagementDiscussion.aspx?id=83&FinCode=132649

1.8 Regulatory Certification

11

1.9 Achievements

Nectar wins "Outstanding Exports Award, 2014-15" by Pharmexcil.

Nectar awarded with the National Energy Conservation award by Beaureu

of Energy Efficiency, Ministry of Power, Govt of India

Nectar honored as the fastest growing pharmaceutical company by CNBC

TV 18 and State Bank of India

Nectar's Chairman Mr Sanjiv Goyal wins "Outstanding Entrepeneurship

Award -2014" by APEA

Nectar breaks into Fortune 500 India, ranking 19th in Indian Pharma

Chapter 2

• 2.1 Company’s Subsidiaries and Plant Location

12

13

Subsidiaries Name Address Country

Nectar lifescience UK limited Devonshire House

60 Goswell Road

London

United kingdom

M/S Chem pharma pvt. ltd. Wagawatta Road,

Horana

Sri Lanka

Sri Lanka

Nectar lifescience USA LLC USA

Type of Products Being

Manufactured

Address State

Formulation Unit and Empty Hard

Gelatin Capsule Unit (2 plants)

Unit III & IV : Village Bhatoli Kalan,

Pargana Dharampur, Tehsil Nalagarh

Solan District

Himachal Pradesh

API and Menthol Plant (8 plants) Vill:Saidapura,

Tehsil:Dehrabasti,

Patiala

Punjab

Menthol Plant (1 Plant) Narbada Industries Plot No. 2, Lane No.

4, Phase II, SIDCO Industrial Complex,

Bari Brahmana

Jammu

Jammu & Kashmir

Plants

Subsidiaries

2.1 Company’s Subsidiaries and Plant Location

Chapter 3

• Company Cash Flow and Financial Status

• 3.1 Balance Sheet

• 3.2 Profit and Loss Statement

• 3.3 Share Holders

• 3.4 Debt Clearance Management

14

15

0

500

1000

1500

2000

2500

3000

1091.441336.38

1406.44 1467.011552.52

1812.62

2120.93

2274.042394.07

2510.47

Liabilities Assets

2011 2012 2013 2014 2015

*Liabilities are increasing at faster rate than Assets

3.1 Balance sheet ( In INR Cr. )

Year

INR

Cr.

16

0

200

400

600

800

1000

1200

1400

1600

1800

1075.52

1326

1042.29

1649.94 1663.64

103.92 73.25 85.67 62.08 66.26

Revenue Profit/Loss After Tax

2011 2012 2013 2014 2015

*Total Revenue has increased, However the profit has been decreasing over a

period of Five year

3.2 Profit & Loss (In INR. Cr.)IN

R C

r.

Year

17

3.3 Share Holders

*Foreign and institutional share holding are less ,which is not a positive sign of the company

0

100

200

300

400

500

600

700

800

900

1000

564.35

928.83

770.07803.18

860.83

103.92 73.25 85.6762.08

66.26

Total Borrowing Profit/Loss After Tax

20152012 2013 20142011

* Total borrowings are increasing at faster rate than profit, No such long term benefits are clearly

visible18

3.4 Debt Clearance Management (In Rs. Cr.)IN

R C

r.

Year

Chapter 4

• Aspects of International Business

• 4.1 Recent one year Export Details

• 4.2 Recent One Year Import Details

• 4.3 Comparison of Revenue Generated from Export

19

Export Items Fall in Following Chapters

4.1 Recent One Year Export Details

Chapter 13

1 Product

Chapter 29

27 Products

Chapter 30

1 Product

Chapter 33

5 Products

Chapter 35

1 Products

Chapter 38

1 Products

Chapter 39

1 Product

20

*NLL exporting products in 82 Countries

Some Of Countries are Given Blow

United States Afghanistan Iraq Saudi Arabia

Japan Argentina Kenya Spain

Egypt Brazil Mexico Switzerland

France Russia Netherlands United Kingdom

21

4.3 Comparison of Revenue Generated from Export

940

960

980

1000

1020

1040

1060

1080

1100

1120

1140

1013

1126

Re

ve

nu

e (

INR

Cr.

)

Year

2015 2016

Chapter 28

2 Product

Chapter 29

22 Products

Chapter 30

3 Product

Chapter 35

1 Products

Chapter 38

2 Products

Chapter 39

1 Products

Chapter 84

1 Product

Chapter 90

8 Product

4.2 Recent One Year Import Details

Import Items Fall in Following Chapters

22

Some Of Countries are Given Blow

Austria United Kingdom Spain Italy

Belgium United States France South African Republic

*NLL importing products from 18 Countries

23

Chapter 5

• 5.1 Company’s Strategies and Future plans

24

5.1 Company’s Strategies and Future plans

Chapter 6

• Overall Analysis and Recommendations from Our Side

25

NSR-backed Nectar Life set to defend winding up suit

The legal tussle between Indian drug makers -- Hetero Drugs and Nectar Lifesciences -- is

moving to the next level as the Punjab and Haryana High Court will hear the winding up

petition filed against Nectar Lifesciences by Hetero Drugs on Thursday.

Earlier, the court had issued a show-cause notice against Punjab-based Nectar Lifesciences

Ltd asking the company why a winding up petition, filed by Hyderabad-based Hetero

Drugs Ltd, should not be admitted against Nectar for alleged default of the long

outstanding dues of Rs 3.2 crore which Nectar is indebted to Hetero Drugs.

26

5.1 Company’s Offence

5.2 Company’s Rating

Nectar Lifesciences

5.8/10 C++

27

Points Obtain Grade Recommendation

10 A++ Highest degree of safety

9 A+ Highest degree of safety

8 B++ High degree of safety

7 B+ High degree of safety

6 C++ Adequate degree of safety

5 C+ Adequate degree of safety

4 D++ Moderate risk

3 D+ Moderate risk

2 E++ Highest Risk

1 E+ Highest Risk

Modifier "+" (plus) / "-"(minus) reflect the comparison within the category.

Rating Methodology

Lifescience Intellipedia Pvt. Ltd.

Suite no- 101, C- 104, Sector- 65 Noida UP- 201301

Contact No- 0120 6900 550-565

Email address- sales@lifescienceintellipedia.com

28

Nothing will improve your credit score faster than paying down debt